Discovery of 6-Diazo-5-oxo-l-norleucine (DON) Prodrugs with Enhanced CSF Delivery in Monkeys: A Potential Treatment for Glioblastoma.

Abstract

The glutamine antagonist 6-diazo-5-oxo-l-norleucine (DON, 1) has shown robust anticancer efficacy in preclinical and clinical studies, but its development was halted due to marked systemic toxicities. Herein we demonstrate that DON inhibits glutamine metabolism and provides antitumor efficacy in a murine model of glioblastoma, although toxicity was observed… (More)
DOI: 10.1021/acs.jmedchem.6b01069

Topics

Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Blog articles referencing this paper

Slides referencing similar topics